JP2018506995A5 - - Google Patents

Download PDF

Info

Publication number
JP2018506995A5
JP2018506995A5 JP2017562971A JP2017562971A JP2018506995A5 JP 2018506995 A5 JP2018506995 A5 JP 2018506995A5 JP 2017562971 A JP2017562971 A JP 2017562971A JP 2017562971 A JP2017562971 A JP 2017562971A JP 2018506995 A5 JP2018506995 A5 JP 2018506995A5
Authority
JP
Japan
Prior art keywords
cells
transgene
cell
sequence encoding
dhfr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017562971A
Other languages
English (en)
Japanese (ja)
Other versions
JP6947647B2 (ja
JP2018506995A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/019288 external-priority patent/WO2016138091A2/en
Publication of JP2018506995A publication Critical patent/JP2018506995A/ja
Publication of JP2018506995A5 publication Critical patent/JP2018506995A5/ja
Application granted granted Critical
Publication of JP6947647B2 publication Critical patent/JP6947647B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017562971A 2015-02-24 2016-02-24 遺伝子改変ｔ細胞の選択方法 Expired - Fee Related JP6947647B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562120329P 2015-02-24 2015-02-24
US62/120,329 2015-02-24
US201562120790P 2015-02-25 2015-02-25
US62/120,790 2015-02-25
US201562175794P 2015-06-15 2015-06-15
US62/175,794 2015-06-15
PCT/US2016/019288 WO2016138091A2 (en) 2015-02-24 2016-02-24 Selection methods for genetically-modified t cells

Publications (3)

Publication Number Publication Date
JP2018506995A JP2018506995A (ja) 2018-03-15
JP2018506995A5 true JP2018506995A5 (enExample) 2019-03-14
JP6947647B2 JP6947647B2 (ja) 2021-10-13

Family

ID=56464271

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017562971A Expired - Fee Related JP6947647B2 (ja) 2015-02-24 2016-02-24 遺伝子改変ｔ細胞の選択方法

Country Status (8)

Country Link
US (2) US10808230B2 (enExample)
EP (2) EP3261656B1 (enExample)
JP (1) JP6947647B2 (enExample)
KR (1) KR20170117095A (enExample)
CN (1) CN107667169B (enExample)
AU (2) AU2016222850B2 (enExample)
CA (1) CA2976126A1 (enExample)
WO (1) WO2016138091A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2997134B1 (en) 2013-05-14 2020-06-24 Board of Regents, The University of Texas System Human application of engineered chimeric antigen receptor (car) t-cells
DK3105335T3 (da) 2014-02-14 2020-01-13 Univ Texas Kimære antigenreceptorer og fremgangsmåder til fremstilling heraf
CA2964783C (en) 2014-11-05 2024-01-23 Board Of Regents, The University Of Texas System Chimeric antigen receptors (car) to selectively target protein complexes
JP6775515B2 (ja) 2015-03-11 2020-10-28 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム トランスポザーゼポリペプチド及びその使用
EP3349791A1 (en) 2015-09-15 2018-07-25 Board of Regents, The University of Texas System T-cell receptor (tcr)-binding antibodies and uses thereof
WO2017075147A1 (en) 2015-10-27 2017-05-04 Board Of Regents, The University Of Texas System Chimeric antigen receptor molecules and uses thereof
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
CA3064000A1 (en) 2017-05-24 2018-11-29 Effector Therapeutics, Inc. Methods and compositions for cellular immunotherapy
CN109136282A (zh) * 2018-09-30 2019-01-04 北京鼎成肽源生物技术有限公司 一种hafft1细胞的构建方法
CA3119599A1 (en) 2018-11-16 2020-05-22 Rapa Therapeutics, Llc Als treatment using induced regulatory t (itreg) cells
WO2020102726A1 (en) * 2018-11-16 2020-05-22 Rapa Therapeutics, Llc Method for manufacturing of human hybrid regulatory t/th2 cells (hybrid treg/th2 cells) from de-differentiated t cells
KR102594009B1 (ko) 2021-02-01 2023-10-24 서울대학교산학협력단 형질전환 생식세포의 제조 방법 및 이를 이용한 형질전환 동물의 제조 방법
EP4408169A4 (en) * 2021-09-30 2025-10-29 Univ Southern California Human hepatocyte culture medium and conditioned medium of in vitro cultured human hepatocyte cells and their uses
CN114740196B (zh) * 2022-04-08 2023-04-18 中南大学湘雅二医院 标志物及其在制备评价机体免疫功能的产品中的应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX340972B (es) * 2008-10-08 2016-08-02 Intrexon Corp Celulas manipuladas por ingenieria que expresan multiples inmunomoduladores, y uso de las mismas.
DK3246042T3 (da) * 2009-11-02 2019-10-14 Univ Emory Lægemiddelresistent immunterapi til behandling af cancer
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
AU2012203048A1 (en) * 2011-05-24 2012-12-13 Agency For Science, Technology And Research IRES mediated multicistronic vectors
WO2013074916A1 (en) 2011-11-18 2013-05-23 Board Of Regents, The University Of Texas System Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
EP2814846B1 (en) * 2012-02-13 2020-01-08 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
EP2997134B1 (en) 2013-05-14 2020-06-24 Board of Regents, The University of Texas System Human application of engineered chimeric antigen receptor (car) t-cells
CA2913052A1 (en) 2013-05-24 2014-11-27 Board Of Regents, The University Of Texas System Chimeric antigen receptor-targeting monoclonal antibodies
US9907820B2 (en) 2013-10-25 2018-03-06 Board Of Regents, The University Of Texas System Polyclonal gamma delta T cells for immunotherapy
JP6976058B2 (ja) * 2013-11-22 2021-12-01 セレクティスCellectis 免疫療法のための化学療法薬耐性ｔ細胞を工学的に作製する方法
DK3105335T3 (da) 2014-02-14 2020-01-13 Univ Texas Kimære antigenreceptorer og fremgangsmåder til fremstilling heraf
SG10201808811QA (en) * 2014-04-10 2018-11-29 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Method and compositions for cellular immunotherapy
US20170158749A1 (en) 2014-04-23 2017-06-08 Board Of Regents, The University Of Texas System Chimeric antigen receptors (car) and methods for making and using the same
KR20160145186A (ko) 2014-04-24 2016-12-19 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 입양 세포 요법 생성물을 생성하기 위한 유도 만능 줄기 세포의 응용
CA2964785A1 (en) 2014-11-05 2016-05-12 Board Of Regents, The University Of Texas System Gene modified immune effector cells and engineered cells for expansion of immune effector cells
CA2964783C (en) 2014-11-05 2024-01-23 Board Of Regents, The University Of Texas System Chimeric antigen receptors (car) to selectively target protein complexes
JP6775515B2 (ja) 2015-03-11 2020-10-28 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム トランスポザーゼポリペプチド及びその使用
EP3349791A1 (en) 2015-09-15 2018-07-25 Board of Regents, The University of Texas System T-cell receptor (tcr)-binding antibodies and uses thereof
WO2017075147A1 (en) 2015-10-27 2017-05-04 Board Of Regents, The University Of Texas System Chimeric antigen receptor molecules and uses thereof

Similar Documents

Publication Publication Date Title
Krueger et al. Two sequential activation modules control the differentiation of protective T helper-1 (Th1) cells
US10472637B2 (en) Gold optimized CAR T-cells
Fazilleau et al. The function of follicular helper T cells is regulated by the strength of T cell antigen receptor binding
Schrama et al. Targeting of lymphotoxin-α to the tumor elicits an efficient immune response associated with induction of peripheral lymphoid-like tissue
Gattinoni et al. T memory stem cells in health and disease
Stritesky et al. The transcription factor STAT3 is required for T helper 2 cell development
US11723962B2 (en) Cell-based neoantigen vaccines and uses thereof
CN111989108B (zh) 利用rna去稳定元件协调基因表达
JP2022043043A (ja) 免疫細胞の有効性および増大を改善する方法
CN115697387A (zh) 抗bcma嵌合抗原受体的用途
BR112020007710A2 (pt) métodos para produzir células que expressam receptor de antígeno quimérico
CN109121413A (zh) 使用靶向核酸纳米载体编程治疗性细胞的组合物和方法
WO2018102761A1 (en) Methods for manufacturing and expanding t cells expressing chimeric antigen receptors and other receptors
CA3026180A1 (en) Human leukocyte antigen restricted gamma delta t cell receptors and methods of use thereof
US20180298349A1 (en) Selection methods for genetically-modified t cells
AU2015339106A1 (en) Compositions and methods of stimulating and expanding T cells
US20220152107A1 (en) Method for expansion and differentiation of t lymphocytes and nk cells for adoptive transfer therapies
US20220241333A1 (en) Modulation of t cell cytotoxicity and related therapy
Beltra et al. Enhanced STAT5a activation rewires exhausted CD8 T cells during chronic stimulation to acquire a hybrid durable effector like state
Metcalfe et al. Ag85A-specific CD4+ T cell lines derived after boosting BCG-vaccinated cattle with Ad5-85A possess both mycobacterial growth inhibition and anti-inflammatory properties
Curtis et al. Fidelity of pathogen-specific CD4+ T cells to the Th1 lineage is controlled by exogenous cytokines, interferon-γ expression, and pathogen lifestyle
Trella et al. CD40 ligand‐expressing recombinant vaccinia virus promotes the generation of CD8+ central memory T cells
US9234175B2 (en) Creating bioengineered lymph nodes
Muthuvel et al. Engineering safe anti-CD19-CD28ζ CAR T cells with CD8a hinge domain in serum-free media for adoptive immunotherapy
TW202400780A (zh) Cd16highcd57highnk-92mi 細胞